MB
EWTX icon

MPM BioImpact’s Edgewise Therapeutics EWTX Stock Holding History

MPM BioImpact’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.3M Buy
1,660,696
+5,440
+0.3% +$157K 4.04% 6
2025
Q4 		$41.1M Sell
1,655,256
-65,485
-4% -$1.31M 4.7% 5
2025
Q3 		$27.9M Hold
1,720,741
– – 4.57% 5
2025
Q2 		$22.6M Buy
1,720,741
+615,297
+56% +$8.87M 3.91% 6
2025
Q1 		$24.3M Buy
1,105,444
+26,128
+2% +$685K 4.18% 4
2024
Q4 		$28.8M Buy
1,079,316
+162,150
+18% +$5.16M 4.09% 3
2024
Q3 		$24.5M Buy
917,166
+176,505
+24% +$3.51M 3.67% 6
2024
Q2 		$13.3M Buy
740,661
+299,402
+68% +$5.22M 2.07% 15
2024
Q1 		$8.05M Buy
+441,259
New +$7.01M 1.29% 32
2023
Q3 		– Sell
-712,798
Closed -$5.52M – 33
2023
Q2 		$5.52M Buy
+712,798
New +$6.01M 1.11% 27
2022
Q4 		– Sell
-304,027
Closed -$2.99M – 39
2022
Q3 		$2.99M Buy
+304,027
New +$3.07M 0.71% 26

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MPM BioImpact's EWTX Position: Q1 2026 in Review

MPM BioImpact increased its Edgewise Therapeutics (EWTX) stake by 0.33% in Q1 2026, buying an estimated $157K and bringing the position to 1,660,696 shares worth $52.3M. The position accounts for 4.04% of the portfolio, ranked #6.

MPM BioImpact first reported a position in EWTX in Q3 2022 and has held it in 11 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • MPM BioImpact held 1,660,696 shares of Edgewise Therapeutics worth $52.3M as of Q1 2026.
  • MPM BioImpact bought 5,440 Edgewise Therapeutics shares in Q1 2026, an estimated $157K.
  • Edgewise Therapeutics made up 4.04% of MPM BioImpact's portfolio in Q1 2026, its #6 holding.
  • MPM BioImpact first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.